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Abstract
Background—Increasingly, evidence from studies in both animal models and patients suggests
that cardiovascular dysfunction is important in HD. Previous studies measuring function of the left
ventricle (LV) in the R6/2 model have found a clear cardiac abnormality, albeit with preserved LV
systolic function. It was hypothesized that an impairment of RV function might play a role in this
condition via mechanisms of ventricular interdependence.
Objective—To investigate RV function in the R6/2 mouse model of Huntington’s disease (HD)
Methods—Cardiac cine-magnetic resonance imaging (MRI) was used to determine functional
parameters in R6/2 mice. In a first experiment, these parameters were derived longitudinally to
determine deterioration of cardiac function with disease progression. A second experiment
compared the response to a stress test (using dobutamine) of wildtype and early-symptomatic R6/2
mice.
Results—There was progressive deterioration of RV systolic function with age in R6/2 mice.
Furthermore, beta-adrenergic stimulation with dobutamine revealed RV dysfunction in R6/2 mice
before any overt symptoms of the disease were apparent.
Conclusions—This work adds to accumulating evidence of cardiovascular dysfunction in R6/2
mice, describing for the first time the involvement of the right ventricle. Cardiovascular
dysfunction should be considered, both when treatment strategies are being designed, and when
searching for biomarkers for HD.
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Introduction
Huntington’s disease (HD) is a hereditary disorder caused by a CAG repeat expansion in the
HTT gene. During the course of the disease, progressive neurodegeneration in the basal
ganglia and cerebral cortex occurs, which causes motor, cognitive and psychological
problems. Neurological symptoms are the most prominent and devastating consequences of
the disease and understandably, over the past two decades, research has focused mostly on
the central nervous system dysfunction and pathology. However, the brain is not the only
organ involved in HD. The gene is ubiquitously expressed and the protein is found in most
peripheral tissues, including skeletal muscle, liver and heart [1]. As a consequence, in
addition to neurological symptoms, HD leads to a number of systemic complications, such
as metabolic dysfunction including cachexia [2, 3].
There is a growing awareness of cardiac dysfunction in HD. Heart failure (HF) is a major
cause of death in HD patients [4-6], and HD patients are 15 times more likely to suffer from
heart disease than age-matched controls [7]. It is well established that HD patients suffer
from impairments in the autonomic nervous system [8] and circadian control [9-12]. These
abnormalities have been found in pre-symptomatic mutation carriers (PHD) and in early-
symptomatic patients, in the form of sleep disturbances and an impaired cardiovascular
response (e.g. diastolic arterial blood pressure and heart rate) to cognitive challenge [11] or
postural changes [10]. It has been suggested that these symptoms are related to loss of
dopamine receptors, microglia activation and neural inclusions in the hypothalamus of PHD
individuals [9], although it is possible that the cardiovascular system is directly involved.
Circadian changes in daily activity patterns have been observed in several mouse models of
HD [13], including R6/2 mice [14-16], R6/1 mice [17] and BACHD mice [16]. Interestingly,
it has been shown that circadian control of autonomic regulation of heart rates was disrupted
in both BACHD [16] and R6/1 mice [17]. Analysis of ECG data in early stage R6/1 mice
revealed different types of arrhythmia, which are thought to be caused by impairments in
cardiovagal modulation [17]. Abnormalities in areas of the brain implicated in autonomic
regulation were also reported. Mild effects on systemic blood pressure and on the size of
myocytes in the R6/1 model have been shown, although gross functional deficits in left
ventricular (LV) function were not observed [17].
While the autonomic nervous system is very likely to play an important role in HD cardiac
dysfunction, some evidence suggests that HF may be a result of direct expression of
huntingtin in cardiomyocytes [7]. Indeed, a recent study has shown that cardiomyocyte-
restricted expression of a protein carrying a polyglutamine repeat can alone induce heart
disease in wildtype (WT) mice, in a way that is dependent on the number of glutamine
repeats and not on the levels of expression of the protein [18]. Expression of low levels of a
peptide containing 83 glutamine repeats caused both deposition of pre-amyloid oligomers
and formation of polyglutamine-containing aggresomes within the cardiomyocytes, leading
to cardiomyocyte loss, progressive cardiac dilation and eventual death from HF by
approximately 5–7 months [19].
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In this study we were interested in investigating the role of the right ventricle (RV) in the
cardiac phenotype seen in R6/2 mice. The R6/2 mouse has proved to be a useful model of
HD, displaying, as it does, neurodegeneration [20, 21], behavioural abnormalities [22-27],
and altered daily activity patterns [14-16]. Cardiovascular function has also been studied in
R6/2 mice using both echocardiogram [28] and magnetic resonance imaging (MRI) [29].
With both approaches, progressive dysfunction with reduced left ventricular (LV) volume
was found previously, though with a preserved LV systolic function [28] [29]. Additionally,
changes in the shape of the LV during systole including bowing of the septum were reported
[29]. To our knowledge, analysis of the RV in this mouse model has never been reported in
literature. Although the RV is known to be involved in many pathological conditions, its
role in disease is less investigated compared to the LV, and is a current focus for
cardiovascular research [30].
Here we hypothesized that an impaired RV function, and therefore reduced pulmonary
circulation, might be an important component of the circulatory problems seen in HD mice.
In this study we used in vivo MRI to determine whether the RV was involved in R6/2
cardiac pathology. We characterised this over time, and also used a pharmacological stress
test (dobutamine) to determine whether or not these effects could be unmasked earlier in the
disease.
Methods
This study was carried out in accordance with the UK Animals (Scientific Procedures) Act,
1986, and with the approval of the University of Cambridge Ethical Review Panel.
Animals
Mice were taken from a colony of R6/2 transgenic mice [31] established at the University of
Cambridge, and maintained by backcrossing onto CBA × C57BL6N F1 female mice.
Genotyping and CAG repeat length measurement were carried out by Laragen (Los Angeles,
CA, USA) as described previously [32]. The R6/2 mice used in this study had a mean CAG
repeat length of 226 ± 7 (mean ± s.d.). Mice were kept in home cages comprising single sex,
single genotype groups. All of the mice lived in an enhanced environment (24). Clean cages
were provided twice weekly with grade 8/10-corncob bedding, and finely shredded paper for
nesting. The mice were maintained on a 12:12 hour light/dark (LD) cycle, at a temperature
of 21–23° C and a humidity of 55 ± 10%. The mice had ad libitum access to water (using
water bottles with elongated spouts) and dry laboratory food (RM3(E) rodent pellets, Special
Diet Services, Witham, UK). In addition, once a day, a mash was prepared for the R6/2 mice
by soaking 100 g dry food in 230 ml water until the pellets were soft and fully expanded.
The mash was placed on the cage floor, improving access to food and water. This feeding
regime has been shown previously to be beneficial [33].
Magnetic Resonance Imaging
Two experiments were performed: the first to evaluate the functional parameters
longitudinally in transgenic mice (n=5) that were not exposed to dobutamine, the second to
Buonincontri et al. Page 3
J Huntingtons Dis. Author manuscript; available in PMC 2014 April 15.
 Europe PM
C Funders Author M
anuscripts
 Europe PM
C Funders Author M
anuscripts
evaluate the difference in the effect of dobutamine on C57BL6 WT (n=6) and R6/2 (n=6)
mice at a presymptomatic timepoint.
Longitudinal characterization—Five male R6/2 mice were scanned at three time points,
designed to capture an initial period before severe symptoms developed (t1=7±1 weeks of
age; mean ± s.d.) and two later scans reflecting different stages of pathology. In R6/2 mice,
body weight increases with development and, after the onset of neurological symptoms, it
falls as a consequence of disease progression [34, 35]. Disease-induced weight loss was
therefore used for pathology staging. To evaluate changes in heart size independently of
bodyweight, a second scan (t2=14±1 weeks of age) was performed when the bodyweight had
decreased to the same point as it was at the initial scan. A third scan was performed at a later
stage of the disease, when the bodyweight was 75% of the initial weight (t3=16±1 weeks of
age).
Stress test—Six male R6/2 mice and six male WT controls (C57Bl6N/CBA) were
scanned at 10 weeks of age. This corresponded to the last time point before the disease
phenotype starts to show and body weight starts to decrease. In addition to the protocol
described below, pharmacological stress was induced with an in situ intraperitoneal (i.p.)
bolus injection of dobutamine (12 µg/g) to induce chronotropic, as well as inotropic and
lusitropic response [36]. For 30 minutes following injection three short axis slices were
acquired in order to observe the changes in LV and RV volumes caused by beta-adrenergic
stimulation.
Imaging protocol—Anaesthesia was induced with 3% isoflurane in 1l/min O2 and
maintained with 1-2% isoflurane in 1l/min O2. A pressure sensor for respiration rate was
used to monitor anaesthesia depth and a rectal sensor was utilised to monitor the core
temperature, which was maintained at 36-37° with the use of a flowing-water heating
blanket. Gating of the MRI sequences was achieved prospectively with electrocardiogram
(ECG). The ECG trace was visually inspected between MRI sequences to identify severe
arrhythmias if present. MRI was performed at 4.7T with a Bruker BioSpec 47/40 system
(Bruker Inc., Ettlingen, Germany). A birdcage coil of 12cm was used for signal excitation
and a 2cm surface coil for signal reception with the animals positioned prone. After initial
localization images, 4-chamber and 2-chamber views were acquired (FISP, TR/TE 7ms/
2.4ms, 13-20 frames, 3.5 cm FOV, 256×256 matrix, 1 mm slice thickness, bandwidth
64kHz, flip angle 20°, NEX 2). Using these scans as a reference, short axis slices were
arranged perpendicularly to both the long-axis views (FISP, TR/TE 7ms/2.4ms, 13-20
frames, 3.5 cm FOV, 256x256 matrix, 1 mm slice thickness, bandwidth 64.1kHz, flip angle
20°, NEX 2). Full LV and RV coverage was achieved with no slice gap with 8-10 slices
following Weissman et al [37].
Data analysis—All of the delineations were performed by a single investigator, blind to
genotype or stage of the disease. Delineation of the LV and RV at each phase of the cardiac
cycle excluded the papillary muscles and trabeculations throughout. The regions from each
slice were combined using Simpson’s rule to provide LV mass as well as end diastolic
volume (EDV), end systolic volume (ESV), stroke volume (SV) and ejection fraction (EF)
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for both LV and RV using Segment v1.9 [38]. To analyse the effects of inotropic
stimulation, ejection fraction from the slices acquired 30 minutes after the injection of
dobutamine was compared with the same slices acquired at baseline performing a paired
Student’s t-test.
In the longitudinal analysis parameters were tested for significant differences using a paired
Student’s t-test. Differences between WT and R6/2 mice were tested with a two samples
different variance t-test.
Results
During MRI examinations, mean heart rates were in the range of 350-450 beats/minute, and
respiratory rates were between 25-65 breaths/minute. Visual inspection of the ECG signals
during the MRI studies did not reveal arrhythmia in any subject.
Cardiac functional parameters and body weight at different stages of the disease in R6/2
mice are shown in Table 1. R6/2 mice develop normally, and body weight increased as
expected in the first 8-10 weeks. Body weight then falls as a result of disease progression.
For this reason, weight was the same at 7 weeks (t1) and 14 weeks (t2), and had declined
further by 16 weeks (t3). No significant change in heart rate was observed due to disease
progression. Nevertheless, we observed a significant decrease in LV mass starting from
middle stage of the disease (t2). At a later stage (t3), we observed a substantial decrease in
cardiac output. The LV volume measurements (Table 1) show a progressive reduction of
EDV and ESV, consistent with the reduced cardiac output, but LVEF was unaffected.
Visual inspection of the short-axis images (Figure 1) showed a substantial impairment of RV
systolic function. Remodelling of the RV was represented by a substantial increase in ESV,
as confirmed by the volumetric measurements (Table 1). RVEF measurements showed
significant deterioration from 71% to 51%.
At 10 weeks of age, when R6/2 mice show no overt symptoms, LV mass and ventricle
volumes were similar in WT and R6/2 mice (Table 2). Furthermore, no significant
differences in LVEF or RVEF were present between WT and R6/2 before inotropic
stimulation. After dobutamine administration, we observed a significant increase in the heart
rate for both groups (p<0.001), although the increase was not significantly different between
the two groups (20 ± 15 % in WT, 30 ± 15 % in R6/2 mice, p>0.10). Nevertheless, under
dobutamine-induced stress, RV systolic function dropped dramatically in the R6/2 mice, but
not in the WT mice (Figure 2). Decrease in RV function of R6/2 mice was driven by a
significant increase in both RVEDV and RVESV (Table 3). LV ejection fraction
significantly increased in both groups (p<0.001), but there was no significant difference in
the effect of dobutamine on LVEF on mice of different genotypes.
Discussion
Heart disease is an important contributor to physical decline and represents one of the major
causes of death in HD patients [4-6]. However, the pathophysiology of heart failure in HD
has been relatively unexplored during the past decades [7]. Recent studies using a
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cardiomyocyte-restricted model were crucial in proving that production of a polypeptide
expressing a polyglutamine repeat is sufficient to cause HF [18]. Nevertheless, an in vivo
model of the disease would also be of great value in understanding not only the mechanisms
behind HF in HD, but also the impact of novel pharmacological strategies that might affect
the circulatory system. Our data add to accumulating evidence that cardiac dysfunction is an
important part of the R6/2 mouse pathological phenotype. In vivo MRI confirmed a
progressive reduction in LV output with disease progression in R6/2 mice, although LVEF
was preserved. This study used only a small number of animals, though the results were
significant and findings were consistent with recent reports [28, 29].
Measurement of LV mass has not previously been performed in vivo in the R6/2 model. We
found significant muscle loss in the myocardium at early to middle stage of the disease. We
also found that muscle loss in the heart is not proportional to the reduction of bodyweight, as
was previously conjectured [29]. R6/2 mice lose body weight from approximately 12 weeks
of age, so body weight at 14 weeks was the same as it had been at 7 weeks. However, there
was a decrease in LV mass of approximately 14% between 7 and 14 weeks time points. This
disproportionate loss in LV mass indicates atrophy that is proportionally greater in the heart
than the rest of the body. These data suggest that heart failure in HD is not merely a
consequence of other symptoms, but may develop in parallel.
Measurements of the RV function showed for the first time a progressive deterioration in
R6/2 mice, which reaches a severe stage by 16 weeks of age. Interestingly, this dysfunction
can be unmasked at the initial stage of the disease using the beta-adrenergic agonist
dobutamine. These results highlight a specific pathology of the RV in R6/2 mice, which
might be useful as a biomarker of HD cardiac pathology in this model. The RV and the LV
are highly interdependent, and in some disease states the dilation of the RV shifts the
interventricular septum toward the left, changing LV geometry. These changes contribute to
a low cardiac output state by decreasing LV distensibility and preload [39]. The measured
impairment in RV function is therefore likely to influence the LV cardiac output seen in
these mice through mechanisms of ventricular interdependence [39], thereby diminishing the
systemic blood supply and contributing to physical decline. Several factors indicate that RV
pathology might be synchronous with, rather than a consequence of, autonomic nervous
system defects. Firstly, this pathology is present in presymptomatic animals, when there are
no explicit signs of severe defects in autonomic nervous system regulation. Secondly, during
inotropic stimulation the RV responds showing a dramatic decrease in systolic function,
whereas heart rate and LV systolic function respond normally as previously seen in WT
mice [40].
The R6/2 mouse model of HD displays LV and RV remodelling, with preserved LV
function and chronotropic response, accompanied by a substantial reduction in LV mass.
Interestingly, our findings resemble those seen in the mdx mouse model of muscular
dystrophy [41]. The mdx mouse is a dystrophin-deficient model that has been characterised
by many investigators over the past 20 years. It shows cardiomyopathy together with
skeletal muscle deficiencies [42]. In mdx mice, RV remodelling begins several months
before LV dysfunction. In common with the present findings in R6/2 mice, these changes
can be unmasked with a dobutamine stress test before overt symptoms are present [43].
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Although the phenotypes appear with different time courses in the two models, the
similarities of the pathology are suggestive of a similar mechanism. As is observed in
muscular dystrophy, the progressive RV dysfunction could be due to pulmonary
hypertension and functional degeneration of the diaphragm muscle [44]. During dobutamine
stimulation, the increased LV contractility is not matched by the RV, contributing to an
elevation of RV pressure and volume [41, 45]. This stress-mediated abnormality represents
an early measure of cardiovascular impairment, anticipating most of the other symptoms of
the disease in the R6/2 mouse model.
During the past 70 years, research on the cardiopulmonary system has lagged behind
compared to work on systemic circulation. In the past, procedures such as Fontaine surgery
and cauterization of the RV lateral wall in dog models have led clinicians to consider the RV
to be ‘unnecessary’ [46]. Only recently have technical developments in echocardiography
and MRI led to renewed interest in the RV, seen in the broader context of the
cardiopulmonary system [46]. Although there is limited information on RV function,
impairment plays a significant part in a number of disease states including valvular heart
disease, congenital heart disease, left HF, complications from heart surgery, idiopathic
pulmonary artery hypertension, chronic pulmonary disease, acute respiratory distress and
sepsis [39, 47]. Furthermore, the extent of RV dysfunction is a predictor of outcome in these
diseases, and in 2006, the National Heart, Lung, and Blood Institute identified RV
physiology as a priority area in cardiovascular research [30]. While respiratory function
during disease progression in HD is gaining interest [48] and is being actively studied in a
clinical trial (IRSCTN72770961), we have been unable to find any accounts measuring RV
function, and we hope that our findings in R6/2 mice will encourage this investigation.
Imaging the RV remains a challenging task because of fibre orientation, complex geometry
and contraction pattern [39]. However, MRI is an accurate tool for measuring RV function
in humans [39], as well as in mice [37], since it is capable of high spatial, temporal
resolution and of arranging oblique slices to form 3D stacks. In small animal systems,
accurate monitoring, gating, in situ drug delivery, and slice planning still pose difficulty and
require a certain degree of expertise. Different heart rates and physical size mean that MRI
protocols optimised for patients need substantial modifications to be efficient in mice [49].
The ability to measure pharmacologically-induced stress in vivo with dobutamine, a drug
that is commonly used in the assessment of patients with suspected coronary artery disease
[50], represents an excellent tool for increasing the sensitivity of cardiac MRI exams in
particular clinical conditions. As dobutamine-stress MRI measurements are suitable for use
in humans, they are an appropriate platform for addressing the effects of novel cardiac drug
treatments in HD mice. In particular, it will be possible to compare changes in cardiac
function induced by cardioprotective agents, drugs acting on blood pressure or on the
function of the diaphragm, with alterations in the longevity and neurological condition in
this model. We believe that increased attention to cardiovascular dysfunction in HD patients
may lead to novel treatment approaches that will be beneficial.
In conclusion, these data add to previous findings of LV pathology in the R6/2 mice by
showing that RV function is also impaired. Importantly, these changes can be unmasked in
young, otherwise asymptomatic animals with the beta-adrenergic agonist dobutamine. Using
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a serial and non-invasive method, this work successfully identified a specific dysfunction of
the cardiovascular system in this model of human disease. More detailed study of the
mechanisms behind these changes may help elucidate the increased mortality from heart
disease seen in HD patients, and lead to new pharmacological strategies designed to improve
the lives of HD sufferers.
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LV left ventricle
RV right ventricle
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Figure 1. Right ventricular function during systole in WT and R6/2 mice
(a) Cartoon of the long axis view of the mouse heart, showing the position of the mid-
ventricular short axis slice seen in (b). (b) Images from mid-ventricular short-axis slices
from WT (upper panels) and R6/2 (lower panels) mice, showing an enlarged RV throughout
systole in 16 weeks old R6/2 mice.
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Figure 2. Changes in ejection fractions during dobutamine stress test
RV = right ventricle, LV = left ventricle.
Data are means ± SEM. *=p<0.05
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Table 1
Cardiac parameters for R6/2 mice at different disease stages.
Age (wk) 7± 1 14± 1 16± 1
(presymptomatic) (symptomatic) (late stage)
mean ± s.d. mean ± s.d. mean ± s.d.
Body weight (g) 23 ± 1 23 ± 1 16 ± 1 **
Heart rate (bpm) 425 ± 40 400 ± 80 375 ± 40
LVM (µl) 76 ± 10 65 ± 7 ** 58 ± 9 *
LVEDV (µl) 42 ± 5 40 ± 5 30 ± 5 *
LVESV (µl) 15 ± 1 11 ± 2 8 ± 4 *
LVEF (%) 65 ± 4 72 ± 6 73 ± 7
LVSV (µl) 28 ± 3 29 ± 5 21 ± 2 *
LVCO (ml/min) 12 ± 1 11 ± 3 8.0 ± 0.7 *
RVEDV (µl) 40 ± 4 42 ± 9 44 ± 6
RVESV (µl) 12 ± 2 14 ± 6 22 ± 6 *
RVEF (%) 71 ± 5 68 ± 10 51 ± 9 *
RVSV (µl) 28 ± 4 29 ± 6 22 ± 2 *
RVCO (ml/min) 12 ± 1 11 ± 3 8.2 ± 0.7 *
*p<0.05,
**p<0.01.
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Table 2
Cardiac parameters in WT and R6/2 mice at 10 weeks, prior to dobutamine
administration.
Baseline values (mean ± s.d.)
Genotype WT R6/2
Age (wk) 10 ± 2 10 ± 2
Body weight (g) 25 ± 5 25 ± 4
LVM (µl) 84 ± 15 79 ± 14
LVEDV (µl) 46 ± 11 43 ± 10
LVESV (µl) 13 ± 5 14 ± 5
LVEF (%) 73 ± 4 68 ± 5
RVEDV (µl) 42 ± 8 38 ± 10
RVESV (µl) 11 ± 3 10 ± 4
RVEF (%) 74 ± 5 75 ± 4
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Table 3
Percentage changes in ventricular volumes caused by dobutamine.
% increase (mean ± s.d.)
Genotype WT R6/2
LVEDV (µl) −32 ± 10 −35 ± 10
LVESV (µl) −71 ± 30 −50 ± 15
RVEDV (µl) −5 ± 15 15 ± 40
RVESV (µl) 30 ± 15 115 ± 50
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